Nuvation Bio
NUVB

Nuvation Bio (NUVB) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
CitigroupInitiated CoverageBuy$12.00Sep 30, 2026
WedbushMaintainedOutperform$11.00Sep 16, 2026
CitizensMaintainedMarket Outperform$10.00Sep 16, 2026
Cantor FitzgeraldInitiated CoverageOverweight—Aug 21, 2026
JP MorganInitiated CoverageOverweight$13.00Aug 18, 2026
RBC CapitalMaintainedOutperform$20.00 from $19.00Aug 7, 2026
HC Wainwright & Co.MaintainedBuy$21.00 from $17.00Jul 27, 2026
WedbushMaintainedOutperform$11.00Jul 23, 2026
Truist SecuritiesMaintainedBuy$13.00 from $12.00Jul 7, 2026
RBC CapitalMaintainedOutperform$19.00 from $20.00Jul 7, 2026
HC Wainwright & Co.MaintainedBuy$17.00May 5, 2026
WedbushMaintainedOutperform$11.00May 5, 2026
RBC CapitalMaintainedOutperform$20.00May 5, 2026
WedbushMaintainedOutperform$11.00Apr 16, 2026
WedbushMaintainedOutperform$11.00Apr 2, 2026
WedbushMaintainedOutperform$11.00Mar 27, 2026
RBC CapitalMaintainedOutperform$13.00 from $12.00Mar 3, 2026
UBSMaintainedNeutral$7.00 from $10.00Mar 3, 2026
WedbushMaintainedOutperform$11.00Feb 10, 2026
RBC CapitalMaintainedOutperform$12.00 from $9.00Jan 21, 2026

Frequently asked questions

  • What is the latest analyst rating on NUVB?

    On Sep 30, 2026, Citigroup initiated coverage of Nuvation Bio at Buy with a price target of $12.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.